Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.bpa.2017.07.003 http://scihub22266oqcxt.onion/10.1016/j.bpa.2017.07.003 C5726453!5726453!29110789     free     free     free Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Best+Pract+Res+Clin+Anaesthesiol 2017 ; 31 (2): 153-66 Nephropedia Template TP {{tp|p=29110789|t=2017. LONG-TERM MANAGEMENT OF END-STAGE HEART FAILURE |pdf=|usr=}}{{29110789}} gab.com Text LONG-TERM MANAGEMENT OF END-STAGE HEART FAILURE JO: Best Pract Res Clin Anaesthesiol http://www.kidney.de/pget.php?&tw=1&pmid=29110789 #FOAvip End-stage heart failure manifests as severe and often relentless symptoms that define the clinical syndrome of heart failure, namely congestion and hypoperfusion. These patients suffer from dyspnea, fatigue, abdominal discomfort and ultimately cardiac cachexia. Renal and hepatic dysfunction frequently further complicate the process. Recurrent hospitalizations, cardiac arrhythmias, and intolerance to standard heart failure therapies are common as the disease progresses. Management focuses on controlling symptoms, correcting precipitants, avoiding triggers, and maximizing therapies with demonstrable survival benefit. Amongst appropriate candidates, advanced therapies such as orthotopic heart transplant (OHT) can significantly extend survival and improve quality-of-life. Left ventricular assist devices (LVADs) have been used with increasing frequency as a bridge to OHT or as destination therapy in appropriately selected candidates where they have a demonstrable mortality benefit over medical therapy. Importantly, a multidisciplinary patient-centred approach is crucial when considering these advanced therapies. Twit Text FOAVip LONG-TERM MANAGEMENT OF END-STAGE HEART FAILURE ????Best Pract Res Clin Anaesthesiol http://www.kidney.de/pget.php?&tw=1&pmid=29110789 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=29110789 #FOAvip English Wikipedia <ref>{{Cite pmid|29110789}}</ref> LONG-TERM MANAGEMENT OF END-STAGE HEART FAILURE #MMPMID29110789 Habal MV; Garan AR Best Pract Res Clin Anaesthesiol 2017[Jun]; 31 (2): 153-66 PMID29110789show ga End-stage heart failure manifests as severe and often relentless symptoms that define the clinical syndrome of heart failure, namely congestion and hypoperfusion. These patients suffer from dyspnea, fatigue, abdominal discomfort and ultimately cardiac cachexia. Renal and hepatic dysfunction frequently further complicate the process. Recurrent hospitalizations, cardiac arrhythmias, and intolerance to standard heart failure therapies are common as the disease progresses. Management focuses on controlling symptoms, correcting precipitants, avoiding triggers, and maximizing therapies with demonstrable survival benefit. Amongst appropriate candidates, advanced therapies such as orthotopic heart transplant (OHT) can significantly extend survival and improve quality-of-life. Left ventricular assist devices (LVADs) have been used with increasing frequency as a bridge to OHT or as destination therapy in appropriately selected candidates where they have a demonstrable mortality benefit over medical therapy. Importantly, a multidisciplinary patient-centred approach is crucial when considering these advanced therapies. äLONG-TERM MANAGEMENT OF END-STAGE HEART FAILURE (epmc).pdf DeepDyve Pubget Overpricing